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Introduction 
The decision to prescribe a medication long term to a 
child must be made with care because of possible 
detrimental effects on normal development. Current 
asthma guidelines advocate the use of inhaled corti- 
costeroids in children with moderate or severe asthma 
(1,2). Corticosteroids administered systemically can 
impair linear growth (3,4) and height (5), possibly as a 
result of subnormal adrenal androgen and/or growth 
hormone (GH) production (6) and direct effects on 
bone and connective tissue growth (7). Although 
administering corticosteroids via inhalation is associ- 
ated with fewer systemic effects compared with oral 
administration, there is recent evidence that consistent 
administration of inhaled corticosteroids can affect 
growth (8,9). The inhaled corticosteroids used most 
commonly in children with asthma are beclomethasone 
dipropionate (BDP) and budesonide. Following a brief 
review of mechanisms by which corticosteroids 
suppress growth, this article will summarise data 
pertaining to the effect of these two agents on growth 
in children with asthma. 
Mechanism of Growth Suppression by 
Glucocorticoids 
The pathogenesis of growth suppression by corticos- 
teroids is complex and multifactorial, involving several 
steps in the cascade of events that leads to linear 
growth. These include inhibition of GH secretion and 
its subsequent action, insulin-like growth factor-l 
activity, collagen synthesis and adrenal androgen 
production (7). The mechanism(s) by which inhaled 
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corticosteroids could exert a suppressive effect growth 
is not well characterised. In contrast to oral corticos- 
teroids, inhaled corticosteroids have not been associ- 
ated with alterations of the GH axis. No significant 
change in GH production was observed in 12 children 
treated with inhaled BDP and budesonide 400 pg daily 
for 2 weeks (10). Similarly, in a 1 yr longitudinal study 
involving 52 asthmatic children (some of whom exhib- 
ited slowed growth), inhaled BDP or budesonide had 
no effect on GH secretion (11). 
Biochemical markers of bone growth and metabo- 
lism have not proved to be useful for predicting or 
detecting adverse effects of inhaled corticosteroids 
on growth. Osteocalcin concentration has a good 
correlation with growth but, even at dosages that 
have been shown to suppress growth in children, 
inhaled corticosteroids have minimal effect on serum 
osteocalcin concentrations and other biochemical 
markers of bone metabolism (12,13). These findings 
have led to speculation that inhaled corticosteroids 
may have an effect on growth that is not mediated 
through an effect on bone (12). 
Effects of inhaled corticosteroids on growth do not 
always correlate well with other measurements of sys- 
temic bioavailability, such as suppression of the hypo- 
thalamic - pituitary ~ adrenal axis. For example, 
Agertoft and Pedersen (13) found that treatment with 
fluticasone propionate 200 pg and 400 pg daily, or 
budesonide 400 pg daily, for 2 weeks in 24 children 
caused a significant reduction in urinary cortisol con- 
centrations compared with placebo; however, only the 
budesonide 400 pg day-1 dosage caused a significant 
reduction in mean lower-leg growth rate. Conversely, 
growth rate can be reduced in the absence of changes in 
cortisol production. In a 7 month study, Doull et al. (9) 
observed a significant reduction in mean linear growth 
rate in children treated with BDP, but these children 
had no significant change in cortisol production. 
Consequently, monitoring adrenal function or serum 
markers of bone metabolism is not useful for predicting 
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or detecting an effect of inhaled corticosteroids on 
growth; careful stadiometric measurements of treated 
children remain essential. 
Effect on Growth Rate 
When discussing studies of the effect of medication on 
growth in asthmatic children, it must be kept in mind 
that physiological delayed puberty and impaired growth 
rate have been observed in children with asthma 
who were not receiving inhaled or oral corticosteroid 
therapy (14). This delay in the growth process is 
thought to be due to effects of asthma itself and may 
result in slowing of early adolescent growth (15) but 
will not necessarily influence final adult height (16,17). 
In studies examining the effect of inhaled corti- 
costeroids on growth, growth rate has generally 
been assessed by measuring statural height or by 
knemometry (measuring the growth velocity of the 
lower leg). Although knemometry is useful for 
detecting changes in linear growth velocity over short 
periods of time, it does not accurately predict 
long-term statural growth (18). 
SHORT-TERM STUDIES 
The results of short-term studies of inhaled BDP and 
budesonide on growth rate are summarised in Table 1. 
It is difficult to form a consensus from these short-term 
studies because patient clinical characteristics differed 
significantly and small numbers of children were stud- 
ied. Bisgaard (19) studied very young children who had 
recurrent wheezing. The children included in the three 
knemometry studies conducted by Wolthers and 
Pedersen (21-23) all had mild asthma and, therefore, 
might not constitute representative candidates for 
inhaled corticosteroids therapy according to current 
guidelines. In addition, the method of administering 
the inhaled corticosteroids differed between studies. 
Results of knemometry studies have not been con- 
sistent even between two studies in comparable groups 
of children (similar age, mild asthma) receiving similar 
dosages of budesonide via the same delivery method. 
In a cross-over study comparing 18 day treatment 
periods of budesonide 200 and 800 ug day-i, both 
dosages were found to reduce significantly the velocity 
of lower-leg growth compared with baseline (21). In 
contrast, a larger, parallel-group study found that 
budesonide 800 ug day-i, but not 200 or 400 yg day-i, 
had a significant effect on lower-leg growth rate 
compared with baseline (22). These inconsistencies 
probably reflect the sensitivity of the measurement 
technique in detecting the (normal) markedly irregular 
pattern of lower-leg growth from week to week. 
Despite these shortcomings, knemometry may indi- 
cate short-term growth-suppressive effects of inhaled 
corticosteroids. Taken as a whole, these short-term 
studies suggest that the effect of inhaled corticos- 
teroids on lower-leg growth rate is dose related, with a 
statistically significant impact being more common at 
dosages 2400 pg day.? Reassuringly, the growth rate 
reduction associated with budesonide 800 ug day-i is 
still less than that associated with an oral prednisolone 
dosage of 2.5 mg day-r (24). 
LONGER-TERM STUDIES 
Until recently, most studies of growth in asthmatic 
children treated with inhaled corticosteroids have 
suffered from flaws in study design. In addition to 
reliance on measurement techniques that do not pre- 
dict long-term growth (i.e. knemometry), these 
studies include a lack of evaluation of pubertal 
status, inappropriate stratification of pubertal status 
by age alone, lack of an adequate untreated control 
group, lack of baseline growth rate data and 
baseline differences in age and height between 
treatment groups. In the discussion of longer-term 
(i.e. >6 months) studies outlined below, however, 
aspects of study design are not analysed; rather, 
the authors’ conclusions regarding the data are 
presented and summarised in Table 2. 
Studies of becolmefhasone dipropionate alone 
Awareness of potential growth-suppressing effects of 
BDP was raised by a cross-sectional study of 346 
asthmatic children, 81 of whom were taking BDP 
200-800 ug day-1 (27). The patients in the BDP group 
were significantly shorter for their age than the con- 
trol group receiving other treatments, although the 
authors stated that is was impossible to determine 
whether this was an effect associated with asthma or 
the treatment. Notably the children in the BDP group 
had a mean age of 10.9 years, compared with 6.6 
years for the control group, and therefore were likely 
to be in the phase of physiological pre-pubertal 
growth deceleration, during which a temporary 
decline in height standard deviation scores would be 
expected. 
Somewhat different results were obtained by Nassif 
et al. (28), who studied growth in 24 children receiving 
alternate-day prednisolone and 32 receiving inhaled 
BDP (mean dosage 532 ug day-l) for a minimum of 6 
months. Both groups of children were smaller than 
average, with initial mean heights on the 35th per- 
centile. Final mean heights showed no change over the 
mean 2 yr follow-up. There was a trend towards an 
inverse correlation of height velocities and dosage of 
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oral and inhaled corticosteroids. However, the authors 
concluded that growth was affected by the disease but 
not by corticosteroid treatment. 
Subsequent studies have supported the absence of a 
clinically significant growth-suppressing effect of BDP. 
In a study of 50 asthmatic children receiving BDP 
750-1500 yg daily for a mean of 19 months, growth 
was found to be normal in 44 of the children (25). Four 
of the children who showed a decrease in height per- 
centile were within the period of pre-pubertal growth 
deceleration and the decrease in height percentile was 
always less than 10 percentile points. Rizzo and Rizzo 
(29) conducted a longitudinal survey of 10 children 
(mean age 8 years) with severe asthma receiving 
21000 ug inhaled BDP daily. Height was measured 
prior to beginning BDP treatment and following 1 yr 
of treatment. After 1 yr, all of the children achieved 
>95% of the growth predicted for them based on the 
pre-treatment height percentiles. Inoue et al. (26) con- 
ducted a retrospective analysis of linear growth in 97 
asthmatic children. Height was measured annually 
from age 12 to 20 years. There were no significant dif- 
ferences in mean height at each age among the 61 
patients who were treated with inhaled BDP (300 ug 
daily for 2-14 yr) and those treated with inhaled 
sodium cromoglycate and/or slow-release theophylline. 
However, some recent studies, some with signifi- 
cantly improved study designs, have shown growth 
inhibition by BDP. A randomised clinical trial compar- 
ing BDP with oral theophylline in children, aged 6-17 
years, with mild to moderately severe asthma demon- 
strated reduced growth in the BDP-treated patients (8). 
Thomas et al. (30) observed six pre-pubertal children 
receiving BDP (300-800 pg daily by MD1 or dry pow- 
der device) who showed a significant reduction in mean 
height velocity during treatment. When the dosage was 
reduced or treatment stopped completely, mean height 
velocity increased. The authors believed the six chil- 
dren to be particularly sensitive to BDP. Finally, Doull 
et al. (9) conducted a parallel-group study comparing 
BDP (400 ug daily via dry powder device) with placebo 
in 94 pre-pubertal children (aged 7-9 years) with mild 
asthma. Over the 7-month study period, mean growth 
rate was significantly lower in the BDP group (0.79 mm 
week-i, P~O.001) and catch-up growth did not occur 
during the 4-month wash-out period. 
Little information is currently available regarding the 
influence of inhaled corticosteroids on growth during 
infancy and early childhood. Treatment for 6 months 
with BDP 200 pg daily, administered via an MD1 and 
spacer plus mask (Aerochamber), had no effect on 
length or height in 12 very young children (mean age 
1.22 years) (38). However, there is some debate over 
whether inhaled corticosteroids should be used in chil- 
dren ~3 years of age because 30 yr follow-up studies 
have now provided evidence of increasingly severe 
asthma or deteriorating lung function in the absence of 
treatment (39). 
The clinical relevance of growth suppression by 
inhaled corticosteroids depends more on the ultimate 
effect on height than (possibly) short-term reductions 
in growth rate. Because BDP was approved for use in 
children earlier than budesonide, more extensive data 
regarding the effect on height are available for BDP. 
Balfour-Lynn (16) followed 66 asthmatic children 
(mean age 7.5 years at entry) for a mean of 13.1 yr, 26 
of whom were receiving inhaled BDP up to 600 ug 
day-l. All grew normally until about 10 years of age. 
Eleven children whose dosage of BDP exceeded 
400 ug day-i showed decelerating growth velocity dur- 
ing a period of delayed onset of puberty, but later 
demonstrated catch-up growth and achieved their pre- 
dicted adult height. There was no significant difference 
between the final heights of children receiving BDP 
and those not receiving inhaled corticosteroid. Finally, 
a meta-analysis (of 21 studies in 810 asthma patients) 
of the effect of oral corticosteroid or inhaled BDP 
on growth showed a small but significant correlation 
between corticosteroid treatment in general and 
reduced final height (5). Growth impairment was 
linked to oral corticosteroid treatment whereas 
inhaled BDP treatment was associated with reaching 
normal height. The statistical evidence did not suggest 
a link between growth impairment and inhaled BDP at 
higher doses, for more prolonged treatment duration 
or among patients with more severe asthma. 
Studies of budesonide alone 
Of six studies examining budesonide in children with 
asthma, none has shown an adverse effect on growth. 
In a large controlled, prospective study (31), 216 chil- 
dren were followed at six-monthly intervals for l-2 yr 
while not receiving inhaled budesonide and then for 
3-6 yr while receiving inhaled budesonide (mean daily 
dosage decreased from 710 to 430 ug over the course 
of the study). No statistically significant changes in 
growth velocity were observed during budesonide 
treatment. Moreover, compared with the control 
group which did not receive inhaled budesonide, chil- 
dren in the budesonide group had improved lung 
function, suggesting that inhaled corticosteroid 
therapy can modify the course of the disease. Three 
small, longer-term studies of budesonide adminis- 
tered at standard dosages have also found no adverse 
effects on growth. Varsano et al. (34) followed 16 
children (mean age 4 years 11 months receiving BUD 
100 l.tg two to four times daily (via MD1 plus spacer) 
over 1 yr. No abnormalities in growth or bone matu- 
ration were observed. Similarly, Ruiz and Price (33) 
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reported normal growth over 1 yr in 15 asthmatic 
children (median age 5.9 years) who had taken budes- 
onide (mean dosage 410 pg daily via MD1 used with 
a spacer) for a mean period of 25 months. Follow-up 
after 3-5 yr of a small number of pre-pubertal 
children treated with budesonide 200 pg day-1 also 
showed no decrement in height percentiles (35). 
Merkus et al. (15) conducted a randomised, double- 
blind study in 40 asthmatic adolescents (mean age 12.8 
years) receiving salbutamol 600 pg daily and inhaled 
budesonide 600 pg daily or placebo for a median 
period of 22 months. Growth rates were matched with 
those of 80 controls. Budesonide treatment was not 
associated with a significant effect on growth velocity 
compared with placebo. Interestingly, males treated 
with either budesonide or placebo showed similar 
slowing of growth rates compared with controls, 
pointing again to a likely confounding effect of 
delayed puberty in the analysis of growth of children 
with asthma. 
In an open study of 40 very young children (mean 
age 1.4 years) with severe asthma, nebulised budes- 
onide (via a face mask) 14 mg daily for a mean dura- 
tion of 6 months did not reduce linear growth (32). 
Indeed, budesonide treatment was associated with a 
small improvement in linear growth (statistically but 
not clinically significant according to the authors). 
Studies of beclomethasone dipropionate, budesonide and 
other inhaled covticosteroid treated children 
Studies investigating the effects of inhaled corti- 
costeroids (BDP and/or budesonide as well as other 
corticosteroids) generally on growth in children with 
asthma have found contradictory results. Ninan & 
Russell (36) followed 58 pre-pubertal children 
receiving inhaled corticosteroids 200-l 600 pg (mean 
800 pg) daily for a mean of 4.9 yr. Height velocity 
changes were measured in boys until they were 
11 years of age and in girls until they were 10 years of 
age and asthma control was assessed by symptom 
scores. The researchers concluded that poor asthma 
control affected growth but that the use of inhaled 
corticosteroids did not. 
However, two other studies have reported evidence 
of impaired growth associated with inhaled corticos- 
teroids. In the study by Saha et al. (37), prior to treat- 
ment with inhaled corticosteroids, mean growth 
velocity in 201 pre-pubertal asthmatic children (l-1 1 
years) was found to be similar to that of healthy peers. 
Growth velocity was impaired in the asthmatic chil- 
dren during BDP or budesonide therapy (average 
dosage 500 pg day I). The growth-retarding effect of 
the inhaled corticosteroids was not dose dependent 
but a longer duration of therapy was linked to a 
greater growth suppression. Although these asthmatic 
children showed similar pre-treatment growth com- 
pared with healthy peers (suggesting that the disease 
itself did not modify growth), more severe asthma was 
associated with a greater reduction in growth rate. 
Crowley et al. (11) performed a 1 yr longitudinal 
study of 56 asthmatic children aged 44-l 1.7 years. All 
13 children not receiving inhaled corticosteroids had 
normal growth velocity whereas ten of 20 receiving 
BDP (mean dosage 560 pg day-l by dry powder device 
or MD1 + spacer) and four of 19 receiving budesonide 
(mean dosage 762 yg day 1 by dry powder device or 
MD1 f spacer) had an impaired growth rate. Children 
receiving inhaled corticosteroids and oral pred- 
nisolone were much more likely to grow slowly: three 
of four showed slow growth. While growth delay was 
also detected in children who did not receive corticos- 
teroids, it was more marked in those receiving inhaled 
corticosteroids, who were also more likely to have 
more severe disease. 
Conclusions 
To date, no comparative studies of the effects of thera- 
peutically equivalent doses of BDP, budesonide and 
other inhaled corticosteroids on long-term growth have 
been conducted. Most short- and long-term studies 
have been confounded by differences in the inhaled cor- 
ticosteroid dosages, delivery devices and the patient 
populations studied. Short-term studies indicate that 
dosages of inhaled BDP and budesonide 2400 pg day-1 
can affect lower-leg growth rate evaluated over a period 
of 2-8 weeks; however, these data do not accurately 
predict long-term growth or final height attained. The 
overall data from longer-term studies suggest that 
dosages of inhaled BDP and budesonide ~400 pg day -1 
do not adversely affect growth rate in asthmatic chil- 
dren. Rarely, growth failure will occur during conven- 
tional dose inhaled corticosteroid therapy, reflecting 
interindividual differences in sensitivity to systemic 
corticosteroid effects following inhalation (40). The 
risk of more frequent and profound growth suppression 
can be expected to increase incrementally with 
uninterrupted administration of doses in excess of 
400 pg/day. In children with allergic rhinitis, clinicians 
must consider total corticosteroid burden during 
concurrent therapy with intranasal corticosteroid. 
Disparities in the results of recent prospective 
studies (showing growth suppression by BDP) and 
retrospective studies (showing minimal or no effect on 
growth rate or height) might be reconciled by consid- 
ering the difference in inhaled corticosteroid dose 
and consistency of administration required to 
achieve disease control rather than symptom control 
(41). Well-designed, prospective studies, with closely 
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monitored and consistent dosing capable of achieving 
disease control, have shown l-1.5 cm yr1 reductions 
in growth rate during BDP therapy 400 pg day-l. On 
the other hand, most patients reduce drug exposure 
over time by titrating medication to achieve symptom 
control only, perhaps accounting for the lack of 
effect of real-life prescriptions of BDP 400 ug day-r 
on retrospective growth rates or final adult 
stature. Marked discrepancies between adherence to 
prescribed therapy as reported by patients and 
actual compliance has been convincingly demon- 
strated (42). Consequently, whether long-term contin- 
uous administration of inhaled corticosteroids at a 
disease-controlling dosage could reduce final height 
remains unknown. 
No reliable surrogate marker for predicting the 
effect of inhaled corticosteroids on growth has yet 
been identified. Careful monitoring of growth of chil- 
dren receiving continuous inhaled corticosteroid 
therapy using a wall-mounted stadiometer is a sensi- 
tive indicator of this adverse effect and should occur 
regularly at 34 month intervals. As with any drug, the 
dosage of inhaled corticosteroid should be tailored to 
the minimum amount that provides reliable control of 
asthmatic symptoms. Moreover, because the growth- 
inhibiting effects of corticosteroids vary not only with 
dosage but with dose frequency and time of exposure, 
receptor affinity, drug absorption and metabolism, 
lipophilicity and other factors, each new strategy in 
inhaled corticosteroid therapy (e.g. higher dosage, 
institution earlier in life, use of more potent formula- 
tions) requires that questions regarding side-effects of 
inhaled corticosteroids be addressed anew (41). 
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